CervoMed Inc. - 8-K Filing
CervoMed completes enrollment in Phase 2a study of neflamapimod for nonfluent variant primary progressive aphasia and announces interim data presentation at CTAD. (Items: 7.01 Regulation FD Disclosure On July 9, 2026, CervoMed Inc, 8.01 The information set forth in the first and third paragraphs of, and under the headings “Recent Nature Neuroscience publication supports inhib, 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No)
Tickers: $CRVO